UAML
CORT icon

US Asset Management LLC’s Corcept Therapeutics CORT Stock Holding History

US Asset Management LLC’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-3,259
Closed -$239K – 116
2025
Q2 		$239K Sell
3,259
-79
-2% -$5.73K 0.21% 109
2025
Q1 		$381K Buy
+3,338
New +$203K 0.36% 76

Other funds holding CORT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

US Asset Management LLC's CORT Position: Q3 2025 in Review

US Asset Management LLC sold out of Corcept Therapeutics (CORT) in Q3 2025, closing a stake of 3,259 shares — an estimated $239K sold.

US Asset Management LLC first reported a position in CORT in Q1 2025 and held it in 2 quarters. The position peaked at $381K in Q1 2025. 429 funds tracked by Wall St. Rank hold CORT as of Q3 2025.

  • US Asset Management LLC reported no remaining Corcept Therapeutics position as of Q3 2025 after selling out during the quarter.
  • US Asset Management LLC sold 3,259 Corcept Therapeutics shares in Q3 2025, an estimated $239K.
  • US Asset Management LLC first reported a position in Corcept Therapeutics in Q1 2025 and held it in 2 quarters.
  • US Asset Management LLC's Corcept Therapeutics position peaked at $381K in Q1 2025.
  • 429 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2025.

Based on US Asset Management LLC's 13F filing for Q3 2025, filed 18 Nov 2025.